Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale
Crossref DOI link: https://doi.org/10.1186/s12944-017-0513-7
Published Online: 2017-06-17
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Teramoto, Tamio
Kondo, Akira
Kiyosue, Arihiro
Harada-Shiba, Mariko
Ishigaki, Yasushi
Tobita, Kimimasa
Kawabata, Yumiko
Ozaki, Asuka
Baccara-Dinet, Marie T.
Sata, Masataka
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals